Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

University of Rochester

Overview

This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Dry Eye Syndromes

Interventions

Platelet Poor Plasma Tear DropsOTHER

Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.

Platelet Rich Plasma Tear DropsOTHER

Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must be diagnosed with clinically significant dry eye. * Subjects have no active ocular disease or allergic conjunctivitis. * Subjects must not be using any topical ocular medications within two weeks prior to enrollment. * Subjects must be willing and able to follow instructions. * Subjects must have voluntarily agreed to participate in the study by signing the statement of informed consent. * Subjects must meet plasma donor criteria as established by University of Rochester Transfusion Medicine \& Blood Bank. Exclusion Criteria: * Is pregnant at the time of enrolment in the study determined by urine pregnancy test. * Is currently on a course of antibiotics * Is considered by the Investigator to not be a suitable candidate for participation and are not at risk for glaucoma. * Is considered by the University of Rochester Transfusion Medicine \& Blood Bank not a suitable candidate for blood donation.

Locations (1)

Flaum Eye Institute at the University of Rochester

Rochester, New York, United States

Outcomes

Primary Outcomes

Mean change in acuity

Acuity will be measured using a Shack-Hartmann Wavefront Sensor. Subjects will be seated in front of the wavefront sensor. They will be asked to blink naturally fixate on the laser spot throughout the measurement protocol. While subjects fixate, the wavefront sensor delivers a brief flash of light to the subjects' retina. The light reflected out of the subjects' eye is collected to obtain measurements of wavefront aberrations of the eye. For optical quality assessments the measurements of wavefront aberrations will be acquired along the line-of-sight. The wavefront data acquired from the wavefront sensor will be described by Zernike coefficients, the most popular mathematical way to represent the ocular aberrations.

Time frame: baseline to 3 months

Mean change in breakup pattern to appear

This will be measured using a Placido Disk. The subject places their chin on a chin rest and look into the disk system. The system uses an incandescent or broad-band area LED for illumination.

Time frame: baseline to 3 months

Mean change in lipid coverage of the cornea with blinking

This will be measured using a Ellipsometer/Tearscope. This instrument uses a modified slit-lamp head restraint and an imaging system to visualize the surface of the subject's cornea. Structurally the system is a clinical slit-lamp system. However, the system uses an electronic camera instead of a human observer. The illumination system uses a diffuse ring illuminator instead of a slit-lamp. The data from this instrument identifies changes in the lipid thickness and the refractive index over the cornea.

Time frame: baseline to 3 months

Mean change in consistency of lipid compensation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.